ArticleLeukemia2018

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

S Degryse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.